Catalyst Crew Technologies Corp. Announces Acquisition of AI Healthcare Assets and Venezuelan Subsidiary

Catalyst Crew Technologies Corp. (“CCTC” or “the Company”) has made a series of significant corporate moves that could materially affect its future growth trajectory and potentially impact shareholder value. The details, contained in a recently filed Form 8-K, reveal the Company’s expansion into artificial intelligence-enabled healthcare analytics and its strategic establishment in Venezuela.

Key Developments

• Acquisition of AI Healthcare Assets: On February 17, 2026, CCTC entered into an Asset Purchase Agreement with its CEO, Kevin Rodan Levy. The Company acquired intellectual property and technology related to artificial intelligence-enabled healthcare analytics platforms. The assets include proprietary software, machine learning models, datasets, and associated intellectual property, specifically patent registrations in Venezuela for CardioAI, PulmoAI, and NeuroAI technologies. The transaction closed around February 20, 2026.
• Completion of Subsidiary Acquisition: On March 23, 2026, CCTC completed the acquisition of 100% of the issued and outstanding shares of Inversiones Long 33, C.A., a Venezuelan corporation. This was executed via a Share Assignment Agreement with CEO Kevin Rodan Levy. As a result, Inversiones Long 33, C.A. is now a wholly-owned subsidiary, intended as CCTC’s operating entity in Venezuela and a cornerstone of its Latin American strategy.
• Intellectual Property Assignment: On April 7, 2026, an Intellectual Property Assignment Agreement was executed, transferring ownership of CardioAI, PulmoAI, and NeuroAI patents and related IP to Inversiones Long 33, C.A. The assignment covers inventions, algorithms, trade secrets, databases, and all rights to enforce and exploit the IP globally.
• Public Announcements: Between March 23 and April 13, 2026, CCTC issued multiple press releases detailing the establishment of its operating structure, assignment of intellectual property, and the launch of its healthcare AI platforms. These releases are available on public platforms including Yahoo Finance.
• Emerging Growth Company Status: CCTC is classified as an “emerging growth company” under SEC rules, which may affect its regulatory compliance and reporting obligations.

Details of Agreements

• Asset Purchase Agreement: The Company acquired assets free and clear of liens or claims, including proprietary technology and patent registrations (VEN-SAPI-2024-033780 for CardioAI, VEN-SAPI-2024-033781 for PulmoAI, VEN-SAPI-2024-033782 for NeuroAI).
• Share Assignment Agreement: Assignor (Kevin Rodan Levy) warrants sole legal ownership of shares, with no restrictions, and full authority to transfer. No third-party consent was required.
• Intellectual Property Assignment Agreement: Assignor (Kevin Rodan Levy) confirms sole and exclusive ownership of the IP, free of encumbrances, with no prior assignment or license. Assignee (Inversiones Long 33, C.A.) gains all rights to use, enforce, and record the IP.

Potential Price-Sensitive Implications for Shareholders

• Strategic Expansion: The acquisition of proprietary AI healthcare platforms and the establishment of a Venezuelan subsidiary mark a substantial pivot for CCTC, positioning the Company in a rapidly growing sector and opening up new markets in Latin America.
• Intellectual Property Ownership: Full control of CardioAI, PulmoAI, and NeuroAI, including patents and associated technology, could provide a competitive advantage and create high entry barriers for competitors.
• Leadership and Governance: All agreements involve the CEO, Kevin Rodan Levy, which concentrates operational and IP ownership in the executive leadership. Shareholders should note the potential governance risks and alignment of interests.
• Regulatory Status: As an emerging growth company, CCTC may leverage reduced regulatory burdens, but shareholders should monitor any changes in compliance or accounting standards that could affect disclosures and transparency.
• Market Communications: Multiple press releases and public disclosures about these developments may catalyze increased investor attention and trading activity.

What Investors Should Watch

• Execution of Latin American Strategy: The success of the Venezuelan subsidiary and AI platform commercialization will be crucial. Investors should monitor subsequent financial results, partnership announcements, and regulatory developments in Venezuela and Latin America.
• Intellectual Property Protection: The enforceability and commercial viability of CardioAI, PulmoAI, and NeuroAI patents, especially in Venezuela and broader markets, will impact revenue potential and competitive positioning.
• Press Release Follow-ups: Future updates on product rollouts, customer acquisition, and regulatory approvals may be price-moving events.

Conclusion

Catalyst Crew Technologies Corp. has executed a series of high-impact transactions—acquiring core AI healthcare assets, securing patents, and establishing a regional subsidiary. These moves signal a strategic focus on Latin American healthcare technology and may materially affect the Company’s growth prospects, competitive position, and ultimately, share price. Investors are advised to monitor further developments, especially as CCTC begins to commercialize its CardioAI, PulmoAI, and NeuroAI platforms and leverages its emerging growth company status to drive expansion.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All information is sourced from SEC filings and public disclosures as of April 13, 2026. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The author does not hold any position in Catalyst Crew Technologies Corp. at the time of writing.

View Catalyst Crew Technologies Corp. Historical chart here